a Center for Ophthalmology , Eberhard-Karls University Tübingen , Germany.
Ocul Immunol Inflamm. 2018;26(4):601-607. doi: 10.1080/09273948.2016.1247872. Epub 2016 Dec 12.
To evaluate the response to treatment in patients with tubulointerstitial nephritis and uveitis (TINU) syndrome over a long-term follow-up period.
Nine patients with TINU syndrome were retrospectively reviewed. The mean follow-up was 54.8 months (range: 24-133 months).
The mean number of recurrences per year declined from 1.7 in the 1st year to 0.66 in the 2nd year of treatment. The ocular inflammation responded to local corticosteroids in two patients, systemic corticosteroids in two patients, immunosuppressive therapy in four patients, and anti-TNF-α blocking agent in one patient. The therapy could be discontinued in six (67%) patients after a mean treatment period of 29.5 months. In five patients, remission with the recurrence-free period of 12.8 months was achieved.
TINU syndrome was characterized by limited responsiveness to corticosteroid therapy and less by severe complications. A long-term course of immunosuppressants or biologics was necessary to control the uveitis and led to induction of remission.
评估 tubulointerstitial nephritis 和 uveitis (TINU) 综合征患者在长期随访期间的治疗反应。
回顾性分析 9 例 TINU 综合征患者。平均随访时间为 54.8 个月(范围:24-133 个月)。
治疗的第 1 年每年复发次数的平均值为 1.7 次,第 2 年下降至 0.66 次。2 例患者局部应用皮质类固醇,2 例患者全身应用皮质类固醇,4 例患者应用免疫抑制剂治疗,1 例患者应用抗 TNF-α 阻断剂治疗。在平均治疗 29.5 个月后,6 例(67%)患者可以停用治疗。5 例患者获得缓解,无复发期为 12.8 个月。
TINU 综合征的特点是对皮质类固醇治疗的反应有限,严重并发症较少。需要长期使用免疫抑制剂或生物制剂来控制葡萄膜炎,从而诱导缓解。